Saturday 17 October 2026
Export NEO’s income statement to Excel — free account
NeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024. In the quarter to June 2026, revenue grew 11.2%, EPS grew 105.7%, free cash flow fell 16.2% and total debt rose 10.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
16.65
0.60
−3.48%
Follow NEO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(12.99%) | (12.42%) | (11.56%) | (6.33%) | |
Piotroski F-Score |
4 | 4 | 4 | 5 | |
| (7.52%) | (7.21%) | (6.73%) | (3.78%) | ||
ROIC |
(7.44%) | (7.11%) | (6.48%) | (4.20%) | |
Return on Tangible Assets |
(30.66%) | (28.98%) | (26.61%) | (14.55%) | |
Average Days of Receivables |
79.93 | 79.91 | 81.92 | 83.55 | |
Free Cash Flow per Share |
(0.13) | (0.15) | (0.02) | (0.04) | |
Free Cash Flow |
(17.05) | (19.71) | (3.02) | (5.29) | |
Capital Expenditures |
(30.74) | (24.94) | (25.44) | (27.34) | |
| Other line items | |||||
Cash ROIC |
(1.27%) | (1.47%) | (0.23%) | (0.40%) | |
Accounts Receivable Turnover |
4.62 | 4.70 | 4.68 | 4.67 | |
Accounts Payable Turnover |
20.50 | 18.48 | 20.14 | 17.74 | |
Inventory Turnover |
15.15 | 14.93 | 14.23 | 14.02 | |
Average Days of Payables |
20.58 | 20.40 | 22.29 | 17.80 | |
Days of Inventory on Hand |
25.91 | 25.24 | 25.68 | 23.05 | |
Tax Rate |
0.00 | (0.02) | (0.03) | (0.05) | |
Research and Development Expense of Revenue |
5.06% | 5.10% | 4.88% | 4.98% | |
Selling, General and Administrative Expense of Revenue |
51.38% | 50.23% | 48.80% | 46.86% | |
Share Based Compensation of Revenue |
5.87% | 5.68% | 5.39% | 4.72% | |
Interest Coverage |
(25.30) | (30.88) | (38.89) | (26.52) | |
Operating CF/Net income |
(0.12) | (0.05) | (0.23) | (0.42) | |
Depreciation/Fixed assets |
0.84 | 0.82 | 0.82 | 0.83 | |
Capex/Depreciation |
(0.43) | (0.36) | (0.37) | (0.41) | |
Revenue per Share |
5.52 | 5.68 | 5.78 | 5.91 | |
Operating CF per Share |
0.11 | 0.04 | 0.17 | 0.17 | |
Capex per Share |
(0.24) | (0.19) | (0.20) | (0.21) | |
Capex to Sales |
0.04 | 0.03 | 0.03 | 0.04 |
Columns are period end dates